Sugi Predict

Sugi Predict / Targets / TRPM7

TRPM7

Transient receptor potential cation channel subfamily M member 7 · Q96QT4 · TRPM7 on Sugi Atlas →

1,456 patent compounds predicted against TRPM7, 1,318 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
Cannabigerolic Acid Cannabigerolic Acid (SCHEMBL9909324) 1.00 1/20
Cannabigerolic Acid Cannabigerolic Acid (SCHEMBL13214109) 1.00 1/20
Cannabigerolic Acid Cannabigerolic Acid (SCHEMBL16429144) 1.00 1/20
SCHEMBL21407458 SCHEMBL21407458 0.98 1/20
SCHEMBL21814616 SCHEMBL21814616 0.98 1/20
SCHEMBL21814620 SCHEMBL21814620 0.98 1/20
SCHEMBL21814621 SCHEMBL21814621 0.98 1/20
SCHEMBL21814632 SCHEMBL21814632 0.98 1/20
SCHEMBL21814641 SCHEMBL21814641 0.98 1/20
SCHEMBL21814624 SCHEMBL21814624 0.94 1/20
SCHEMBL13214111 SCHEMBL13214111 0.85 1/20
SCHEMBL19714693 SCHEMBL19714693 0.85 1/20
SCHEMBL19591975 SCHEMBL19591975 0.84 1/20
SCHEMBL22036745 SCHEMBL22036745 0.84 1/20
SCHEMBL21814611 SCHEMBL21814611 0.82 1/20
SCHEMBL22106052 SCHEMBL22106052 0.82 1/20
SCHEMBL23465512 SCHEMBL23465512 0.82 1/20
SCHEMBL17042886 SCHEMBL17042886 0.79 1/20
SCHEMBL17042888 SCHEMBL17042888 0.79 1/20
SCHEMBL21814630 SCHEMBL21814630 0.79 1/20

Clinical trials — most relevant to TRPM7 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Symptom Response in Normal and Dry Eye Patients Secondary to Application of a Menthol-Containing Eyedrop (Rohto® Hydra) PHASE4COMPLETED
Mechanisms of Capsaicin Treatment in Idiopathic Rhinitis Patients and Controls PHASE4COMPLETED
Investigator Initiated Trial Using Dry Eye Surveys to Evaluate and Better Understand FDA Approved Acoltremon Treatment for Dry Eye Disease in Real World Treatment Settings (DESERT) PHASE4NOT_YET_RECRUITING
Switching From Restasis to TRYPTYR PHASE4NOT_YET_RECRUITING
The Re-Prosper HF Study PHASE2/PHASE3COMPLETED
TRPM8 Activators for Peripheral Neuropathy PHASE2ACTIVE_NOT_RECRUITING
Early Study on Tamoxifen Safety/Tolerability in Cystic Fibrosis Patients Unable to Use CFTR Modulators. PHASE2NOT_YET_RECRUITING
Calcium Channel Blockade in Primary Aldosteronism PHASE2COMPLETED
Safety and Efficacy of MEM 1003 Versus Placebo in Patients With Mild to Moderate Alzheimer's Disease PHASE2COMPLETED
Assessment of KM-001 - Safety, Tolerability, and Efficacy in Patients With PPPK1 or PC PHASE1COMPLETED
Study Designed to Evaluate Safety and Efficacy of 1% Topical Formulation of KM-001 on Type 1 Punctate Palmoplantar Keratoderma or Pachyonychia Congenita Diseases PHASE1COMPLETED
The Role of Coenzyme Q10 in the Prophylaxis of Oxaliplatin Induced Peripheral Neuropathy in Patients With Colorectal Cancer PHASE1RECRUITING
Mechanism of Human Cold Pain Perception - Involvement of TRPA1, TRPM8, Nav1.7 and Nav1.8 EARLY_PHASE1COMPLETED
Mechanisms of Human Heat Perception - Involvement of TRPA1, TRPV1 and TRPM3 EARLY_PHASE1COMPLETED
Menthol Stimulation of Brown Adipose Tissue in Humans: Aim 1 EARLY_PHASE1RECRUITING
Characterization of New Human Models of Non-histaminergic Itch and Their Interaction With the TRPM8 Receptor nanCOMPLETED
Identification of TRP Channels as New Potential Therapeutic Targets in Primary and Secondary Raynaud's Phenomenon. nanCOMPLETED
TRPM2 Gene Polymorphism, NLRP3 Inflammasome Expression in Vitiligo Patients nanACTIVE_NOT_RECRUITING
Factors Affecting Salt Intake in Young Adults nanUNKNOWN
The Natural History of TRPV4 Neuropathy nanRECRUITING
An Investigation Into the Mechanism of Inhalation Cough Challenge nanCOMPLETED
The Involvement of ATP Sensitive Potassium Channel in Migraine Aura and Migraine Pain. nanUNKNOWN
Dissecting the Heterogeneity of Oral Cancer Pain nanUNKNOWN
Neurogenic Mechanisms in Burning Mouth Syndrome nanCOMPLETED
Effects of an Anti-TRPM8 in the Atopic Dermatitis Pruritus nanCOMPLETED
Investigation of a New Human Model for Itch nanCOMPLETED
Relationship Between Polymorphisms of TRPV1 and KCC2 Gene in Children With Febrile Seizures nanCOMPLETED
Qutenza 8% Capsaicin Topical System for the Treatment of Neuropathic Axial Lower Back Pain and Lumbosacral Radiculopathy nanENROLLING_BY_INVITATION
Effects of Photobiomodulation on the Innate Immune System of Neonates and Infants With Bronchiolitis nanUNKNOWN
Manganese-Enhanced Magnetic Resonance Imaging (MEMRI) in Ischaemic, Inflammatory and Takotsubo Cardiomyopathy (MEMORY) nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a TRPM7 binder may also engage these)

ProteinNameSimilarity
Q925B3 — 1.000 Q925B3 →
Q923J1 — 1.000 Q923J1 →
TRPM6 Transient receptor potential cation channel subfamily M member 6 0.995 landscape →
Q7Z4N2 — 0.993 Q7Z4N2 →
TRPM8 Transient receptor potential cation channel subfamily M member 8 0.992 landscape →
A0A0R4IMY7 — 0.988 A0A0R4IMY7 →
Q8R455 — 0.988 Q8R455 →
J9SQF3 — 0.987 J9SQF3 →
Q9HCF6 — 0.987 Q9HCF6 →
Q8CIR4 — 0.986 Q8CIR4 →
S5UH55 — 0.985 S5UH55 →
Q8R4D5 — 0.985 Q8R4D5 →
Q2TV84 — 0.984 Q2TV84 →
A8DYE2 — 0.982 A8DYE2 →
Q2WEA5 — 0.980 Q2WEA5 →
Q5R981 — 0.976 Q5R981 →
PIK3CG Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform 0.974 landscape →
Q9VRR2 — 0.972 Q9VRR2 →
Q6R8G5 — 0.972 Q6R8G5 →
P35574 — 0.971 P35574 →
Q99LC3 — 0.971 Q99LC3 →
Q90ZC7 — 0.971 Q90ZC7 →
Q6NX27 — 0.971 Q6NX27 →
Q21029 — 0.971 Q21029 →
Q6PST4 — 0.971 Q6PST4 →
Q6R8G7 — 0.971 Q6R8G7 →
Q9UPR0 — 0.970 Q9UPR0 →
Q28BK1 — 0.970 Q28BK1 →
Q53P98 — 0.970 Q53P98 →
Q8NHH9 — 0.970 Q8NHH9 →